Braveheart Bio Readies Global Pivotal Trial After Strong Phase 2 Data for HCM Drug BHB-1893

New updates have been reported about Braveheart Bio.

Braveheart Bio is advancing its lead cardiac myosin inhibitor, BHB-1893, toward a global pivotal trial in 2026 after a Phase 2 dose-ranging study in obstructive hypertrophic cardiomyopathy showed rapid and substantial reductions in left ventricular outflow tract gradient with minimal impact on ejection fraction. In the 42-patient, multi-center study, up to 86% of patients achieved a complete gradient response below 30 mmHg by week 12, with average gradient reductions evident as early as day 5.

The data, presented as late-breaking clinical research at the American College of Cardiology meeting, also point to a simplified dosing strategy, with 89% of patients adequately controlled on 40 mg or 60 mg twice daily and requiring little or no titration, which could ease real-world adoption and monitoring costs. Safety was favorable, with mostly mild to moderate adverse events, no treatment interruptions or discontinuations, and no ejection fraction values dropping below 55% over 12 weeks.

Group 2, the twice-daily 40 mg arm selected for open-label extension, demonstrated additional clinical benefits, including improved peak oxygen consumption, better Kansas City Cardiomyopathy Questionnaire clinical summary scores, and an 88% reduction in NT-proBNP, underscoring the potential for both symptomatic and biomarker-driven improvement. All 42 patients rolled into the extension, where the complete gradient response rate reached 88% at week 39, supporting durability of effect.

For Braveheart, which holds exclusive rights to develop and commercialize BHB-1893 outside mainland China, Hong Kong, Macao, and Taiwan under its partnership with Hengrui Pharma, these results strengthen the asset’s positioning as a potential best-in-class therapy and key value driver. Management highlights that the emerging efficacy, safety, and ease-of-use profile may address limitations of current oHCM treatments and expand use across a broader patient base.

Strategically, the company is now focused on finalizing the design and operational footprint of its global registrational program, leveraging extensive Phase 2 and regional Phase 3 data generated with its partner. As a late clinical-stage private biotech backed by leading life science investors, Braveheart’s near-term value inflection will center on execution of the pivotal trial, regulatory engagement, and potential expansion into non-obstructive HCM, where a separate Phase 2 study is ongoing.